Elafibranor, a dual PPARα and PPARδ agonist, reduces alcohol-associated liver disease: Lessons from a mouse model

doi:10.3748/wjg.v31.i4.99312

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2691)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series.

Item

Count

PDF

HTML

1694

Figures (1-1)

384

Sum=2167

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

328

Sum=386

Jan 28, 2025 (publication date) through Nov 3, 2025

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastroenterol. Jan 28, 2025; 31(4): 99312
Published online Jan 28, 2025. doi: 10.3748/wjg.v31.i4.99312

Open in New Tab Full Size Figure Download Figure

Figure 1 Schematic diagram of study protocol inducing alcohol-associated liver disease and beneficial effects of elafibranor on liver steatotic disease. ALD: Alcohol-associated liver disease; CCl₄: Carbon tetrachloride.

Citation: Pirola L. Elafibranor, a dual PPARα and PPARδ agonist, reduces alcohol-associated liver disease: Lessons from a mouse model. World J Gastroenterol 2025; 31(4): 99312
URL: https://www.wjgnet.com/1007-9327/full/v31/i4/99312.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i4.99312